Fairvalue-Calculator Fairvalue-Calculator
EN DE

BCWORLD PHARM. Co (200780) Fair Value & Analysis

Healthcare · KR · Market cap 36.7B KRW

Price3,125 KRW
Fair Value2,143 KRW
Upside-31.4%
Quality94/100
Evidence: Medium Range 1,090 KRW – 3,879 KRW

Fair value as of: Jun 24, 2026

Analysis

BCWORLD PHARM. Co (200780) currently trades at 3,125 KRW, while our model-based Fair Value estimate is 2,143 KRW — implying the stock looks roughly 31.4% overvalued today. We read business quality at 94/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).

About the company

BCWORLD PHARM. Co., Ltd. operates as a pharmaceutical company in South Korea. The company provides products in various therapeutic areas comprising musculoskeletal system, digestive system, circulatory machine, central nervous system, adrenocorticosteroids, narcotic analgesics, erectile dysfunction treatment, wellbeing injection, diuretic, antitussive expectorant, vaginitis treatment, anti-tuberculosis drugs, anti-emetic, antiviral drugs, antibiotic, anti-malignant tumor drugs, antifungal agent, antihistamines, antidote, and antipyretic/analgesic/anti-inflammatory. BCWORLD PHARM. Co., Ltd. was founded in 1980 and is headquartered in Seongnam-si, South Korea.

Open the full interactive analysis →

Similar stocks

Frequently asked questions

Is BCWORLD PHARM. Co (200780) undervalued?
As of Jun 24, 2026, our model estimates a fair value of 2,143 KRW versus a price of 3,125 KRW — about −31% (overvalued). Model-based estimate, not financial advice.
What is the fair value of 200780?
Our 21-model fair value for BCWORLD PHARM. Co is 2,143 KRW (as of Jun 24, 2026), built from audited fundamentals. The current price is 3,125 KRW.
What is the quality score of 200780?
BCWORLD PHARM. Co has a Quality Score of 94/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.